First PREMIER Bank grew its holdings in AbbVie Inc (NYSE:ABBV) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,233 shares of the company’s stock after buying an additional 690 shares during the quarter. First PREMIER Bank’s holdings in AbbVie were worth $623,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Lavaca Capital LLC boosted its holdings in AbbVie by 69.2% during the second quarter. Lavaca Capital LLC now owns 49,404 shares of the company’s stock worth $3,593,000 after buying an additional 20,213 shares during the last quarter. Horseman Capital Management Ltd boosted its holdings in AbbVie by 45.5% during the second quarter. Horseman Capital Management Ltd now owns 16,000 shares of the company’s stock worth $1,164,000 after buying an additional 5,000 shares during the last quarter. Ironwood Investment Counsel LLC boosted its holdings in AbbVie by 7.9% during the second quarter. Ironwood Investment Counsel LLC now owns 9,171 shares of the company’s stock worth $666,000 after buying an additional 675 shares during the last quarter. Cedar Wealth Management LLC bought a new position in AbbVie during the second quarter worth about $44,000. Finally, Ballentine Partners LLC boosted its holdings in AbbVie by 52.1% during the second quarter. Ballentine Partners LLC now owns 12,168 shares of the company’s stock worth $886,000 after buying an additional 4,169 shares during the last quarter. Institutional investors own 68.14% of the company’s stock.
A number of equities analysts have issued reports on ABBV shares. ValuEngine upgraded AbbVie from a “strong sell” rating to a “sell” rating in a report on Monday, September 30th. UBS Group upgraded AbbVie from a “neutral” rating to a “buy” rating and cut their price objective for the company from $85.00 to $79.00 in a report on Thursday, September 12th. Citigroup upgraded AbbVie from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $87.00 to $90.00 in a report on Thursday, September 26th. Cowen set a $90.00 price objective on AbbVie and gave the company a “buy” rating in a report on Tuesday, September 24th. Finally, Wolfe Research upgraded AbbVie from an “underperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $89.97.
NYSE ABBV traded down $0.51 during trading on Friday, hitting $73.94. The stock had a trading volume of 1,554,295 shares, compared to its average volume of 7,972,179. The company has a market capitalization of $108.71 billion, a PE ratio of 9.35, a P/E/G ratio of 1.50 and a beta of 0.99. The company’s 50-day moving average price is $70.30 and its two-hundred day moving average price is $73.90. AbbVie Inc has a 12 month low of $62.66 and a 12 month high of $94.98.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 26th. The company reported $2.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.21 by $0.05. The firm had revenue of $8.26 billion for the quarter, compared to analysts’ expectations of $8.09 billion. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.00 EPS. Sell-side analysts expect that AbbVie Inc will post 8.9 EPS for the current year.
The business also recently declared a — dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be given a dividend of $1.07 per share. This represents a dividend yield of 6.4%. The ex-dividend date is Friday, October 11th. AbbVie’s dividend payout ratio (DPR) is 54.11%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: Hold Rating
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.